Synlogic (SYBX) Competitors $1.23 +0.00 (+0.08%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. VNRX, IFRX, VTVT, HOWL, CELU, CNTX, RNXT, ANVS, PRLD, and ADVMShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include VolitionRx (VNRX), InflaRx (IFRX), vTv Therapeutics (VTVT), Werewolf Therapeutics (HOWL), Celularity (CELU), Context Therapeutics (CNTX), RenovoRx (RNXT), Annovis Bio (ANVS), Prelude Therapeutics (PRLD), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Its Competitors VolitionRx InflaRx vTv Therapeutics Werewolf Therapeutics Celularity Context Therapeutics RenovoRx Annovis Bio Prelude Therapeutics Adverum Biotechnologies VolitionRx (NYSE:VNRX) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Is VNRX or SYBX more profitable? Synlogic has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Synlogic N/A -207.84%-114.81% Do institutionals & insiders hold more shares of VNRX or SYBX? 8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 10.4% of VolitionRx shares are owned by insiders. Comparatively, 3.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, VNRX or SYBX? VolitionRx has higher revenue and earnings than Synlogic. VolitionRx is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.31M50.06-$35.32M-$0.27-2.35Synlogic$8K1,805.57-$57.28M-$2.51-0.49 Does the media refer more to VNRX or SYBX? In the previous week, VolitionRx had 3 more articles in the media than Synlogic. MarketBeat recorded 5 mentions for VolitionRx and 2 mentions for Synlogic. VolitionRx's average media sentiment score of 0.52 beat Synlogic's score of 0.44 indicating that VolitionRx is being referred to more favorably in the media. Company Overall Sentiment VolitionRx Positive Synlogic Neutral Does the MarketBeat Community believe in VNRX or SYBX? Synlogic received 316 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 20.83% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformVolitionRxOutperform Votes1520.83% Underperform Votes5779.17% SynlogicOutperform Votes33169.54% Underperform Votes14530.46% Do analysts rate VNRX or SYBX? VolitionRx currently has a consensus price target of $3.50, suggesting a potential upside of 450.49%. Given VolitionRx's stronger consensus rating and higher possible upside, equities analysts clearly believe VolitionRx is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, VNRX or SYBX? VolitionRx has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. SummaryVolitionRx beats Synlogic on 12 of the 19 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.45M$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E Ratio-0.308.4326.6419.64Price / Sales1,805.57262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book0.276.536.974.60Net Income-$57.28M$143.25M$3.23B$248.06M7 Day Performance1.23%0.21%-0.98%-1.03%1 Month Performance12.23%10.92%7.70%3.50%1 Year Performance-23.77%2.44%31.32%12.68% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic1.2736 of 5 stars$1.24+0.4%N/A-24.5%$14.45M$8K-0.3080Short Interest ↑VNRXVolitionRx1.9742 of 5 stars$0.53+5.2%$3.75+608.9%-13.9%$54.50M$1.31M-1.4780Analyst UpgradeGap DownHigh Trading VolumeIFRXInflaRx3.3917 of 5 stars$0.81+0.9%$6.60+714.8%-49.7%$54.38M$129.75K-0.7560Short Interest ↑Analyst RevisionVTVTvTv Therapeutics1.6746 of 5 stars$16.91+6.4%$35.50+109.9%-24.8%$54.03M$17K-3.739Positive NewsHOWLWerewolf Therapeutics3.8416 of 5 stars$1.20-0.8%$8.33+594.4%-58.0%$53.85M$1.14M-0.7840CELUCelularity0.5313 of 5 stars$2.24+6.2%N/A-45.7%$53.65M$54.22M-0.85220Gap DownCNTXContext Therapeutics3.0713 of 5 stars$0.59+1.9%$6.00+920.4%-67.4%$52.75MN/A-0.657Gap UpRNXTRenovoRx2.9503 of 5 stars$1.42+1.4%$7.00+393.0%+16.2%$51.93M$240K-2.496Positive NewsShort Interest ↓High Trading VolumeANVSAnnovis Bio2.0704 of 5 stars$2.63+11.9%$34.75+1,221.3%-51.5%$51.25MN/A-0.593Analyst RevisionPRLDPrelude Therapeutics3.2404 of 5 stars$0.91+2.4%$4.00+341.0%-74.2%$51.22M$7M-0.51120Positive NewsGap DownADVMAdverum Biotechnologies3.9509 of 5 stars$2.43+9.5%$26.40+986.4%-67.1%$50.77M$1M-0.41190Short Interest ↑Gap Down Related Companies and Tools Related Companies VolitionRx Competitors InflaRx Competitors vTv Therapeutics Competitors Werewolf Therapeutics Competitors Celularity Competitors Context Therapeutics Competitors RenovoRx Competitors Annovis Bio Competitors Prelude Therapeutics Competitors Adverum Biotechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
